Since the start of the pandemic, SARS-CoV-2 has already infected more than 250 million
people globally, with more than five million fatal cases and huge socio-economic losses. In …

Hepatitis C virus (HCV) vaccines, designed to augment specific T-cell responses, have been
designated as an important aspect of effective antiviral treatment. However, despite the …

Introduction: Developing a vaccine against HCV is an important medical and global priority.
Unavailability and potential dangers associated with using attenuated HCV viral particles for …

Hepatitis C virus (HCV) causes chronic and acute hepatitis infections. As there is extreme
variability in the HCV genome, no approved HCV vaccine has been available so far. An …

Introduction: Around 3% of the world population is infected with HCV, with 3–4 million newly
infected subjects added to this reservoir every year. At least 10% of these people will …

Abstract Background Hepatitis C virus (HCV) genomic variability is a major challenge to the
generation of a prophylactic vaccine. We have previously shown that HCV specific T-cell …

Chlamydia psittaci is an intracellular pathogen and causes variety of deadly infections in
humans. Antibiotics are effective against C. psittaci however high percentage of resistant …

Context: Plants transformed by virus-based vectors have emerged as promising tools to
rapidly express large amounts and inexpensive antigens in transient condition. Objective …

Correlation of hepatitis C virus (HCV) spontaneous resolution with Th1 and CD8+ CTL
responses during natural infection implies the potentiality of poly-CTL-epitopic HCV …

Hepatitis C virus (HCV) infection is a concerning health issue that causes chronic liver
diseases. Despite many successful therapeutic outcomes, no effective HCV vaccines are …